Main Article Content
Abstract
Keywords
Article Details
-
Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:
Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
You are free to :
Share ” copy and redistribute the material in any medium or format.
Adapt ” remix, transform, and build upon the material.
References
- Alldredge BK, Corelli RL, Ernst ME, et al (2013). Koda-kimble & young's applied therapeutics: the clinical use of drugs, 10th Ed. Philadelphia, Lippincott Williams & Wilkins
- Bleyer WA and Dedrick RL (1978). Clinical pharma-cology of intrathecal methotrexate i pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treatment Reports Vol 61, 703-8
- Borsi JD and Moe PJ (1987). A comparative study on pharmacokinetics of methotrexate in a dose range of 0,5 g to 33,6 g/m2 in children with acute lympho-blastic leukemia. Cancer Vol 60, 5-13
- Hallworth MJ and Capps NE, 1993. Therapeutic drug monitoring and clinical biochemistry. London, ACB Venture Publications, p 70-73
- Hempel L, Misselwitz J, Fleck C, et al (2003). Influence of high dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Medical Pediatric Oncology Vol 40, 348-354
- Jacobs SA, Stoller RG, Chabner BA, et al (1976). 7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. The Journal of Clinical Investigation Vol 57, 534-538
- Kliegman RM, Stanton BF, St. Geme JW, et al (2016). Nelson Textbook of Pediatrics, 20th Ed. Philadelphia, Elsevier, p 2437-244
- Lennard L (1999). Therapeutic drug monitoring of antimetabolic cytotoxic drug. British Journal of Clinical Pharmacology Vol 47, 131-143
- Odoul F, Le Guellec C, Lamagnere JP, et al (1999). Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukemia using a population pharmacokinetic appro-ach. Fundamental Clinical Pharmacology Vol 13, 595-604
- Rau T, Erney B, Gores R, et al (2006). High-dose methotrexate in pediatric acute lymphoblastic leuke-mia: Impact of ABCC2 polymorphisms on plasma concentration. Clinical Pharmacology Therapy Vol 80, 468-76
- Sahnl V, Choudhury D, Ahmed Z (2009). Chemo-therapy-associated renal dysfunction. Nature Reviews Nephrology Vol 6, 450-462
- Xu WQ, Zhang LY, Chen XY, et al (2014). Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Che-motherapy Pharmacology Vol 73, 79-86
References
Alldredge BK, Corelli RL, Ernst ME, et al (2013). Koda-kimble & young's applied therapeutics: the clinical use of drugs, 10th Ed. Philadelphia, Lippincott Williams & Wilkins
Bleyer WA and Dedrick RL (1978). Clinical pharma-cology of intrathecal methotrexate i pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treatment Reports Vol 61, 703-8
Borsi JD and Moe PJ (1987). A comparative study on pharmacokinetics of methotrexate in a dose range of 0,5 g to 33,6 g/m2 in children with acute lympho-blastic leukemia. Cancer Vol 60, 5-13
Hallworth MJ and Capps NE, 1993. Therapeutic drug monitoring and clinical biochemistry. London, ACB Venture Publications, p 70-73
Hempel L, Misselwitz J, Fleck C, et al (2003). Influence of high dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Medical Pediatric Oncology Vol 40, 348-354
Jacobs SA, Stoller RG, Chabner BA, et al (1976). 7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. The Journal of Clinical Investigation Vol 57, 534-538
Kliegman RM, Stanton BF, St. Geme JW, et al (2016). Nelson Textbook of Pediatrics, 20th Ed. Philadelphia, Elsevier, p 2437-244
Lennard L (1999). Therapeutic drug monitoring of antimetabolic cytotoxic drug. British Journal of Clinical Pharmacology Vol 47, 131-143
Odoul F, Le Guellec C, Lamagnere JP, et al (1999). Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukemia using a population pharmacokinetic appro-ach. Fundamental Clinical Pharmacology Vol 13, 595-604
Rau T, Erney B, Gores R, et al (2006). High-dose methotrexate in pediatric acute lymphoblastic leuke-mia: Impact of ABCC2 polymorphisms on plasma concentration. Clinical Pharmacology Therapy Vol 80, 468-76
Sahnl V, Choudhury D, Ahmed Z (2009). Chemo-therapy-associated renal dysfunction. Nature Reviews Nephrology Vol 6, 450-462
Xu WQ, Zhang LY, Chen XY, et al (2014). Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Che-motherapy Pharmacology Vol 73, 79-86